NeuMoDx™ Plans to Add CE-IVD Assay for HPV

Ann Arbor, MI (October 16, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today an agreement with Self-screen BV to implement a CE-IVD marked molecular diagnostic test for high-risk strains of human papillomavirus (HPV) on the NeuMoDx™ 288 and NeuMoDx™ 96 Molecular Systems. HPV is the virus regarded as the major cause of cervical cancer.

“Self-screen is a leader in developing innovative molecular tests for the diagnosis of genital cancers and adding this important women’s health assay to our fully automated continuous random-access NeuMoDx™ systems will help in the global battle to prevent cervical cancer. This agreement represents the next step in our strategy to expand our systems’ content menu by collaborating with key assay partners,” said Jeff Williams, Chairman and CEO of NeuMoDx™.

The HPV assay developed by Self-screen is a real-time PCR-based test that detects15 recognized high-risk genotypes of human papillomavirus DNA. Under the agreement, Self-screen will handle regulatory processes to obtain CE-IVD marking for the assay on the NeuMoDx™ systems, while NeuMoDx™ will manufacture and sell the assay.

QIAGEN, a global leader in Sample to Insight solutions for molecular testing, is the exclusive distributor of the NeuMoDx™ 288 and NeuMoDx™ 96 Molecular Systems in Europe and other major markets outside the United States, while NeuMoDx™ covers the United States directly. Under a 2018 merger agreement, QIAGEN has the right to acquire the remaining 80% of NeuMoDx™ shares that it does not currently own until mid-2020.

Self-screen BV, a biotech spinoff company of VU University Medical Center in Amsterdam, the Netherlands, was founded in 2008 to advance the implementation of scientific discoveries in cancer screening. Self-screen’s main focus is cervical cancer screening and prevention. QIAGEN now markets two CE-IVD tests created by Self-screen, the QIAscreen HPV PCR Test for detection of high-risk HPV, and the QIAsure Methylation Test, a complementary test for use in differentiating patients’ risk of developing cervical cancer.

HPV is the most common viral infection of the genital tract and the major cause of cervical cancer, the fourth most common cancer among women. The World Health Organization (WHO) reported an estimated 570,000 new cases of cervical cancer and 311,000 deaths in 2018. Almost 300 million women globally are estimated to be infected with HPV, and about 30 million additional cases have progressed to the precancerous stage.

NeuMoDx™ Molecular designs and develops revolutionary molecular diagnostic solutions for hospital and clinical reference laboratories. Our patented, ‘sample-to-result’ platform offers market-leading ease of use, true continuous random-access, and rapid turnaround time while achieving optimal operational and clinical performance for our customers and the patients they serve. For more information visit www.neumodx.com.


We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible.

To learn more, click here.